Costa Rica vs Saudi Arabia: Prevalence rate of hypertension in men aged 30-79
Costa Rica
36
in 2019
Saudi Arabia
36.3
in 2019
Costa Rica rank
111th
Saudi Arabia rank
109th
Prevalence rate of hypertension in men aged 30-79 over time
- Costa Rica
- Saudi Arabia
How they compare
Saudi Arabia currently reports 36.3 against 36 in Costa Rica, a difference of 0.3.
The two have swapped places 2 times across 30 shared years of data; in 1990 it was Saudi Arabia ahead.
Costa Rica ranks 111th and Saudi Arabia ranks 109th of 195 countries.
Across the 3 decades both report, Costa Rica averaged higher in 2 and Saudi Arabia in 1.
Head to head by decade
| Decade | Costa Rica | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 33.15 | 34.82 | 1.67 | Saudi Arabia |
| 2000s | 35.82 | 35.6 | 0.22 | Costa Rica |
| 2010s | 36.38 | 35.97 | 0.41 | Costa Rica |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Costa Rica or Saudi Arabia?
- Saudi Arabia, at 36.3 against 36 in Costa Rica as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Costa Rica and Saudi Arabia?
- 0.3, with Saudi Arabia ahead.
- How many years of comparable data are there for Costa Rica and Saudi Arabia?
- 30 years are reported by both, from 1990 to 2019.
- How do Costa Rica and Saudi Arabia rank globally for prevalence rate of hypertension in men aged 30-79?
- Costa Rica ranks 111th and Saudi Arabia ranks 109th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.